Additionally, Chen X found that in the sub-population of NSCLC patients receiving non-gemcitabine regimens, the survival in patients with genotype of XRCC3 ThrThr was significantly longer than those with ThrMet or MetMet. Here, XRCC3 is linked to non-small cell lung carcinoma.